Evaluation of the vaccine candidate CIGB-230 in individuals with chronic renal insufficiency for the prevention of hepatitis C virus infection. Phase I/II clinical trial, controlled, randomized, blinded, adaptive.

Trial Profile

Evaluation of the vaccine candidate CIGB-230 in individuals with chronic renal insufficiency for the prevention of hepatitis C virus infection. Phase I/II clinical trial, controlled, randomized, blinded, adaptive.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs CIGB 230 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top